Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting

B NUTLEY, N.J., April 9, 2026 /PRNewswire/ — Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name:…
posteditor
posteditor
Articles: 16137

Other News